BackgroundFor many years, surgery has been the standard treatment for patients with early-stage non-small cell lung cancer (NSCLC). Recent randomized trials demonstrated that cisplatin-based adjuvant chemotherapy increases overall survival. The aim of this study was to analyze the precise use of adjuvant chemotherapy in patients with resected NSCLC in routine practice.Patients and MethodsBetween January 2004 and May 2005, we retrospectively analyzed 219 patients with early-stage NSCLC who had undergone surgery at one major surgical center in Paris, Institut Mutualiste Montsouris. Patient characteristics, the type of surgery, and indications for adjuvant chemotherapy were analyzed.ResultsEighty-seven of the 219 patients (40%) in this study h...
AbstractBackgroundPlatin-based adjuvant chemotherapy has extended survival in clinical trials in pat...
For many years adjuvant chemotherapy has been a standard treatment after complete resection in malig...
Radical surgery remains the only treatment with curative potential for patients with operable non-sm...
BackgroundFor many years, surgery has been the standard treatment for patients with early-stage non-...
Background:Lung cancer remains a leading cause of cancer-related mortality in North America. Despite...
AbstractCisplatin must be considered the treatment standard for lung cancer chemotherapy, whatever t...
For many years, surgery alone was the standard treatment for patients with stage I-IIIA non-small-ce...
For many years, surgery alone was the standard treatment for patients with stage I-IIIA non-small-ce...
For many years, surgery alone was the standard treatment for patients with stage I-IIIA non-small-ce...
IntroductionAdjuvant chemotherapy in non-small cell lung cancer (NSCLC) has become a new standard of...
AbstractCisplatin must be considered the treatment standard for lung cancer chemotherapy, whatever t...
BACKGROUND: To evaluate the effects of administering chemotherapy following surgery, or following su...
AbstractThe past decade has witnessed renewed interest in studies exploring the benefits of adjuvant...
Cisplatin must be considered the treatment standard for lung cancer chemotherapy, whatever the disea...
Background:Lung cancer remains a leading cause of cancer-related mortality in North America. Despite...
AbstractBackgroundPlatin-based adjuvant chemotherapy has extended survival in clinical trials in pat...
For many years adjuvant chemotherapy has been a standard treatment after complete resection in malig...
Radical surgery remains the only treatment with curative potential for patients with operable non-sm...
BackgroundFor many years, surgery has been the standard treatment for patients with early-stage non-...
Background:Lung cancer remains a leading cause of cancer-related mortality in North America. Despite...
AbstractCisplatin must be considered the treatment standard for lung cancer chemotherapy, whatever t...
For many years, surgery alone was the standard treatment for patients with stage I-IIIA non-small-ce...
For many years, surgery alone was the standard treatment for patients with stage I-IIIA non-small-ce...
For many years, surgery alone was the standard treatment for patients with stage I-IIIA non-small-ce...
IntroductionAdjuvant chemotherapy in non-small cell lung cancer (NSCLC) has become a new standard of...
AbstractCisplatin must be considered the treatment standard for lung cancer chemotherapy, whatever t...
BACKGROUND: To evaluate the effects of administering chemotherapy following surgery, or following su...
AbstractThe past decade has witnessed renewed interest in studies exploring the benefits of adjuvant...
Cisplatin must be considered the treatment standard for lung cancer chemotherapy, whatever the disea...
Background:Lung cancer remains a leading cause of cancer-related mortality in North America. Despite...
AbstractBackgroundPlatin-based adjuvant chemotherapy has extended survival in clinical trials in pat...
For many years adjuvant chemotherapy has been a standard treatment after complete resection in malig...
Radical surgery remains the only treatment with curative potential for patients with operable non-sm...